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Abstract
Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor
receptor (HER) family, plays a critical role in regulating multiple cellular processes including
proliferation, differentiation, cell migration and cell survival. Deregulation of the EGFR signal-
ing has been found to be associated with the development of a variety of humanmalignancies
including lung, breast, and ovarian cancers, making inhibition of EGFR the most promising
molecular targeted therapy developed in the past decade against cancer. Human non small
cell lung cancers (NSCLC) with activating mutations in the EGFR gene frequently experience
significant tumor regression when treated with EGFR tyrosine kinase inhibitors (TKIs),
although acquired resistance invariably develops. Resistance to TKI treatments has been
associated to secondary mutations in the EGFR gene or to activation of additional bypass sig-
naling pathways including the onesmediated by receptor tyrosine kinases, Fas receptor and
NF-kB. In more than 30–40% of cases, however, the mechanisms underpinning drug-resis-
tance are still unknown. The establishment of cellular and mouse models can facilitate the
unveiling of mechanisms leading to drug-resistance and the development or validation of
novel therapeutic strategies aimed at overcoming resistance and enhancing outcomes in
NSCLC patients. Here we describe the establishment and characterization of EGFR TKI-
resistant NSCLC cell lines and a pilot study on the effects of a combinedMET and EGFR
inhibitors treatment. The characterization of the erlotinib-resistant cell lines confirmed the
association of EGFR TKI resistance with loss of EGFR gene amplification and/or AXL overex-
pression and/orMET gene amplification and MET receptor activation. These cellular models
can be instrumental to further investigate the signaling pathways associated to EGFR TKI-
resistance. Finally the drugs combination pilot study shows thatMET gene amplification and
MET receptor activation are not sufficient to predict a positive response of NSCLC cells to a
cocktail of MET and EGFR inhibitors and highlights the importance of identifying more reliable
biomarkers to predict the efficacy of treatments in NSCLC patients resistant to EGFR TKI.
PLOS ONE | DOI:10.1371/journal.pone.0143333 November 18, 2015 1 / 22
OPEN ACCESS
Citation: Presutti D, Santini S, Cardinali B, Papoff G,
Lalli C, Samperna S, et al. (2015) MET Gene
Amplification and MET Receptor Activation Are Not
Sufficient to Predict Efficacy of Combined METand
EGFR Inhibitors in EGFR TKI-Resistant NSCLC
Cells. PLoS ONE 10(11): e0143333. doi:10.1371/
journal.pone.0143333
Editor: Jung Weon Lee, Seoul National University,
REPUBLIC OF KOREA
Received: July 31, 2015
Accepted: November 3, 2015
Published: November 18, 2015
Copyright: © 2015 Presutti et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: GR was partially funded by Project
FaReBio di Qualità, a grant from the Italian Ministry of
Economy and Finance to the CNR and the CNR
Project “Personalised Medicine”. The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor
receptor (HER) family controls key cellular programs, including survival, proliferation, differ-
entiation and migration during development and adult life [1, 2]. EGFR gene is either mutated
or shows altered expression in a variety of human cancers. Lung is the most frequent cause of
cancer-related mortality worldwide leading to over a million deaths each year [3]. Based on his-
tological characteristics, the two principal types of human lung cancer are small cell lung can-
cer (SCLC) and non small cell lung cancer (NSCLC); the latter being the most commonly
detected type contributing to nearly 85% of cases. Identification of all driver oncogene alter-
ations in lung adenocarcinoma and consequently adoption of molecular target therapies is
challenging because of a large burden of passenger events per tumor genome [4–7]. NSCLC
patients, whose tumors harbor EGFR sensitizing mutations in exon 19/21, get a meaningful
clinical benefit from EGFR TKI treatments. However, despite an initial response to these inhib-
itors, most patients ultimately develop drug resistance, followed by relapses [8–18]. Several
clinical studies have shown that a secondary mutation in the tyrosine kinase domain of EGFR
(T790M) is responsible for the development of resistance to EGFR-targeting TKIs in approxi-
mately half of the cases of lung adenocarcinoma [19–21]. Acquired NSCLC resistance to TKIs
has also been associated to overexpression and activation of other receptor tyrosine kinases
(RTKs) including HER3, AXL or MET [22–26], to modulation of Fas receptor and NF-kB sig-
naling pathways [27] and to epithelial to mesenchymal transition (EMT) [28–30].
The MET receptor and its ligand, hepatocyte growth factor (HGF), have recently been iden-
tified as novel promising targets in several human malignancies, including NSCLC. MET
receptor mediates multiple biological responses promoting tissue remodeling, wound repair,
organ homeostasis and cancer metastasis. In several solid tumors,MET gene amplification,
mutations or overexpression lead to constitutively activated MET receptor [31, 32].MET
amplification occurs in 5–20% of NSCLC patients and its amplification or up-regulation corre-
lates with acquired resistance to EGFR TKI treatments [25, 26, 33]. MET amplification can
occur in NSCLC also before treatment with TKIs [34]. For all above reasons MET could
become a valuable target for cancer therapy and several drugs targeting MET or its ligand HGF
are currently undergoing early phase clinical trials in various cancers [35–37].
The identification of model systems to investigate or validate strategies to disrupt EGFR-
dependent tumor cell growth is critical and may provide the basis for clinical applications.
Therefore we decided, as others, to develop and characterize NSCLC cell lines resistant to
EGFR TKIs. In our cellular model system we observed, as previously reported, association of
EGFR TKI-resistance with loss of EGFR mutated allele amplification and/or AXL overexpres-
sion and/orMET gene amplification and MET receptor activation. Moreover, we demonstrated
thatMET gene amplification and MET receptor activation are not sufficient to predict a posi-
tive effect of a combination of MET and EGFR inhibitors in erlotinib resistant NSCLC, suggest-
ing the need of identifying other biomarkers in order to move towards a precision medicine
treatment in NSCLC patients.
Material and Methods
Material
Cells, Antibodies, and Reagents. The human cell lines: HCC827 (ATCC1 CRL-2868™)
and HCC4006 (ATCC1 CRL-2871™), kindly provided by Oreste Segatto, were cultured in
RPMI 1640 medium (BioWhittaker, Lonza, USA) supplemented with 10 mMHepes pH 6.98–
7.30, 1 mM L-glutamine, 100 U/ml penicillin/streptomycin (BioWittaker, Lonza) and heat
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inactivated 10% fetal bovine serum (FBS) (Sigma-Aldrich). All cells were cultured at 37°C in a
5% CO2 humidified incubator. Erlotinib (ERL)-resistant cell lines (RA1, RA2, RB1, RB1.1, RB2
and RC2.2) established essentially as previously described [29] were cultured in the same
experimental conditions. Briefly, HCC827 and HCC4006 parental cell lines were cultured in
complete tissue culture medium with a stepwise increase of erlotinib concentrations (stepwise
method), or a high concentration of erlotinib (1 μM) (high-concentration method) over 5–6
months.
The primary antibodies: EGFR (clone D09, kindly provided by O. Segatto); phosphorylated-
EGFR (Tyr1068); HER2/ErbB2 (D8F12); HER3/ErbB3 (D22C5); HER4/ErbB4 (111B2); phos-
pho-HER2/ErbB2 (Y1221/1222) (6B12); phospho-HER3/ErbB3 (Y1289) (D1B5); phospho-
HER4/ErbB4 (Y1284) (21A9); p44-42 MAPK (ERK1/2) (#9102), phospho-p44-42 MAPK
(ERK1/2) (T202/Y204) clone E10; c-MET (D1C2); phospho-c-MET (Y1234/1235) (D26); Akt
and phospho-Akt (S473), clone D9E were from Cell Signaling Technology (CST); AXL
(#AF154) and phospho-AXL (Y779) (#AF228) were from R&D Systems; GAPDH, clone 1D4
or #5174 was respectively from Novus Biologicals or CST. Secondary antibodies: goat anti-rab-
bit IgG (H+L)-HRP and goat anti-mouse IgG (H+L)-HRP were from Bio-Rad; donkey anti-
goat IgG-HRP (sc 2020) was from Santa Cruz Biotechology; streptavidin Alexa Fluor-488 were
from Life Technologies. Biotin-labeled horse anti-rabbit Ig was from Vector Laboratories Bur-
lingame, CA, USA. Tyrosine kinase inhibitors: Erlotinib Hydrochloride Salt, gefitinib Free
Base, Vandetanib Free Base Lapatinib, Imatinib and Paclitaxel were from LC Laboratories,
USA; SU11274, PHA-665752 hydrate and PF-04217903 were from Sigma-Aldrich, AZD9291,
Rociletinib (CO-1686, AVL-301) and R428 (BGB324) were from Selleckchem and distributed
by DBA Italia. Stock solutions of 10 mM for all inhibitors were prepared in DMSO and stored
at -20°C or -80°C. MTT, 3-(4,5-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was
from Sigma-Aldrich. MTT stock solution (5 mg/ml in H2O, sterilized by filtration) was stored
at 4°C for 1 months. Power SYBR Green PCR Master Mix was from Applied Biosystems. TRI-
zol reagent was from Life Technologies, Reverse Transcription System was from Promega.
Methods
Cell growth inhibition MTT assay. Cells (10–20.000 cells/well) plated in 96-well plates at
day 0 were treated at day 1 with increasing concentrations of TKIs (from 64 pM up to 10–
20 μM if not otherwise stated) in complete tissue culture medium and cultured for 72 hours at
37°C in 5% CO2. Next, cells were gently washed with 1x PBS, incubated for 4 hours with MTT
and processed for color detection with DMSO. The resulting purple solution was spectrophoto-
metrically measured at 570 nm as previously described [38–39]. The optical density values,
obtained by MTT assay reading, of cells treated with drugs were expressed as percentage of cell
survival and normalized with the value of cells treated with vehicle (DMSO). For the EGFR
stimulation, serum starved cells (24 hours) were treated, in RPMI supplemented medium, with
EGF (100 ng/ml) or vehicle (DMSO) for 8 minutes or 100 nM erlotinib for 30 minutes, 1–3
hours. Next, cells were harvested in 1x PBS supplemented with 0.5 mMNa3VO4.
Western blot analysis. Total cell lysates were prepared by rinsing the cells 2 times in ice
cold PBS 1x and by using ice-cold RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mMNaCl, 1%
NP40, 0.25% sodium deoxycholate, 1 mM EDTA) containing a combination of protease and
phosphatase inhibitors (1 μg/ml aprotinin, 2 μg/ml leupeptin, 10 mM NaF, 20 mM β-glicero-
phosfate, 10 mM Na pyrophosphate, 1 mM PMSF, 1 mMNa3VO4). EGFR stimulated cells
were lysed in 50 mMHepes pH 7.5, 150 mMNaCl, 5 mM EGTA, 1% Triton X100 and prote-
ases and phosphatase inhibitors. Cell lysates were quantified for proteins content with the Bio-
Rad DC Protein Assay kit.
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Cell lysates (25–40 μg) were separated by 8–10% SDS-PAGE and transferred to nitrocellu-
lose membranes 0.45 μm (GE Healthcare Life Sciences). The membranes were blocked with 5%
non-fat milk in 1x TBS pH 7.6–8.0 containing 0.1 or 0.2% Tween 20 (TBST) or 2% BSA
(Sigma-Aldrich) for 2 hour at room temperature (RT) and subsequently probed with primary
antibodies in 5% non-fat milk or 2–5% BSA in TBST, as recommended by the manufacturer,
overnight at 4°C. Then membranes were washed 10 minutes for 3 times with TBST and probed
with horseradish peroxidase-conjugated secondary antibodies in 5% non-fat milk in TBST for
1 hour at RT. Chemidoc XRS Bio-Rad was used for images acquisition with a chemi-lumines-
cent camera, band signals were quantified using ImageLab 4.0 Bio-Rad software.
Soft agar assays. Soft agar assays were performed essentially as previously described [40].
Briefly 1.5 ml of 0.7% of Bacto-Agar (Becton Dickinson) in RPMI medium was plated in 35
mm petri dishes (bottom layer). Next, cells (20.000 cells/plate), in 0.35% Bacto-Agar, were
plated on each bottom layer (top layer). Cells were cultured at 37°C in a 5% CO2 humidified
incubator for 2–3 weeks. Plates were stained with a 0.005% crystal violet/20% methanol solu-
tion and images recorded with an Olympus XM10 camera and processed using Olympus Cell-
Sens Standard 1.8.1 software. Finally colonies with a diameter>50 μmwere counted with the
ImageJ software. The percentage of colony forming efficiency (CFE) was calculated according
to the formula: (number of colonies formed/number of cells seeded) x 100. Approximately
500–1000 colonies/plates; 4/7 plates for each cell lines were recorded and analysed by Image J
software.
Ethics statement. All animal studies were carried out in accordance to experimental pro-
tocols as reviewed and approved by the CNR-IBCN animal care and use committee and the
Public Veterinary Health Department of the Italian Ministry of Health (Rome, Italy)
(IBCN-CNR– 0003357) according to the ethical and safety rules and guidelines for the use of
animals in biomedical research provided by the relevant Italian laws and European Union’s
directives.
Xenograft in nude mice. Athymic nude female mice (Foxn1nu/Foxn1+) (Harlan Laborato-
ries) were housed in individually ventilated cages (IVC) under controlled conditions (20–22°C;
55–65% relative humidity; 12/12 hours light/dark cycle; irradiated standard diet and water ad
libitum). To generate tumor xenografts, groups of 3–5 mice 5–10 weeks old were injected sub-
cutaneously with NSCLC tumor cells (5–15 x 106 cells in 200 μl 1x PBS) into the dorsal flanks
of each mouse. Two independent experiments were performed with each NSCLC cell line.
Tumor volume was calculated by caliper measurements of tumor length (L) and width (W)
according to the formula: LxW2/2. Tumor size and body weight were measured twice per week.
Differences in tumor sizes formed on both flanks of mice injected with erlotinib resistant cell
lines were compared to their parental counterpart. To evaluate time to fold tumor volume
increase, normalization of tumor volumes was done to the average tumor volume at day 3,
within the experiment and across xenograft groups. Times to four and six fold increase from
initial tumor volumes (day 3) were assessed. When the tumor volumes reached an average of
approximately 0.6–0.8 cm3 mice, previously euthanized with intra-peritoneal injections of Tile-
tamine/Zolazepam (800 mg/kg) and Xylazine (100 mg/kg), were sacrificed and tumors were
harvested, measured, photographed, and pathologically examined.
Excised tumors were fixed with 3.7% paraformaldehyde (PFA) (wt/vol) 1x PBS for 20 min
at room temperature and then embedded in paraffin. Serial sections 8 μm thick were cut from
the paraffin embedded tissue blocks and floated onto charged glass slides (Super-Frost Plus,
Fisher Scientific, Pittsburgh, PA) and dried overnight at 60°C. Sections were deparaffinized in
changes of xylene and rehydrated in decreasing concentrations of ethanol and rinsed in 1×
PBS. For antigen retrieval, samples were boiled for 10 min in 10 mM sodium citrate buffer (pH
6.0) and cooled for 5–10 min in water. Slides were washed in 1× PBS and incubated with
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blocking buffer (1× PBS, 0.1% Triton X-100, 1% BSA, 4% donkey serum) for 1 h and then incu-
bated overnight at 4°C with primary antibodies diluted in blocking buffer. The following day
slides were washed three times with washing buffer (1× PBS, 0.1% Triton X-100), incubated
with biotinylated anti-Ig secondary antibody for 5 h followed by streptavidin Alexa 488, and
finally washed as before and mounted using Mowiol 4–88 mounting media. Nuclei were
stained using Hoechst 33258 (Sigma Aldrich). For xenograft studies, all tumors were also
stained with the omission of primary antibody as a negative control. For confocal analysis
Argon ion laser at 488 nm and blue diode laser at 405 were used as excitation sources. Confocal
Z-stacks were collected at 0.5 μm intervals to a total optical depth of 8–10 xm. Confocal images
were processed with Volocity (Improvision, Perkin Elmer) and Adobe Photoshop CS4 software
for image rendering and representation of x/y view. Images for direct comparison were col-
lected under same parameters and representative images were chosen.
Genomic DNA preparation. Cell pellets (approximately 10x106 cells) were lysed in
10 mM Tris-HCl pH 8.0, 200 mMNaCl, 2 mM EDTA pH 8.0. Then lysates were brought to
400 mMNaCl, 0.6% SDS, 300 μg/ml proteinase K and incubated overnight at 55°C in water
bath. Saturated NaCl (0.3 volumes) was added and the samples were vigorously mixed followed
by spinning at 14000 rpm at 4°C for 15 minutes. The supernatant was precipitated and the
DNA dissolved in TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA). Afterwards genomic
DNA was treated with RNAse A to remove contaminant RNA. Genomic DNA was incubated
in 300 μl of TE buffer and 15 μl of RNAse A (1 μg/μl) in a 65°C water bath for 10 minutes.
Then, RNAse A was precipitated with 0.4 volumes of 7.5 M ammonium acetate for 30 minutes
at 4°C, centrifuged at 13000 rpm for 30 minutes at 4°C. The supernatant was precipitated with
absolute ethanol. After washes with 70% ethanol, genomic DNA was resuspended in TE buffer.
Mutation analysis by direct sequencing. EGFR exons 19 and 20 and KRAS exons 2 and 3
were amplified by PCR (for primer pairs see S1 Table). Amplified products were then purified
using Exostar 1-Step (VWR International) according to the manufacturer's instructions.
Sequencing reactions were performed using the Big Dye Terminator version 3.1 (Applied Bio-
systems, Foster City, CA, USA). Dye purification was carried out by Centrisep Spin columns
(Princeton Separation) and subsequent sequencing analysis was resolved on a 3130XL Genetic
Analyzer (Applied Biosystems). Sequences were finally analyzed with Sequence Analysis v5.2
and SeqScape v2.5 (Applied Biosystems).
Relative quantitation of gene copy number. Differences in EGFR andMET gene copy
number between ERL-resistant and parental cell lines were determined by quantitative real-
time PCR (qPCR) using an Applied Biosystems 7500 Fast Real-Time PCR System (Applied
Biosystems). PCRs were carried out in 20 μl volume containing 5 ng of genomic DNA, 200 nM
each primer forMET, EGFR and Ribonuclease P (RNase P), in independent reactions (S1
Table) and 1x Power SYBR Green PCR Master Mix (Applied Biosystems). PCRs for each
primer set were performed in triplicate, and mean values were calculated. Quantification was
based on the standard curve method. RNase P was used as a reference gene, to normalize quan-
titation of target genes for differences in the amount of total DNA in each sample. Genomic
DNA of HCC827 and HCC4006 parental cell line were used as calibrator samples, relative to
which differences in gene copy number have been calculated. The data were analyzed using
SDS (Ver. 1.4) software (Applied Biosystems).
RNA analysis. For quantitative RT-PCR analysis, total RNA was extracted using the TRI-
zol (Life Techologies) reagent and retro-transcribed with the Reverse Transcription System
(Promega) using oligo (dT) and random primers. qPCR analysis was performed using a 7500
Fast Real-Time PCR System (Applied Biosystems). PCRs were carried out in 20 μl volume con-
taining 10 ng of total RNA, 200 nM of each primer and 1X Power SYBR Green PCR Master
Mix (Applied Biosystems). Ribosomal protein L31 (rp-L31) was used as a reference gene, to
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normalize quantitation of target genes for differences in the amount of total RNA in each sam-
ple. Total RNA of HCC827 and HCC4006 parental cell lines were used as calibrator samples,
relative to which differences in the RNA amount of resistant cell lines have been calculated.
The data were analyzed using SDS (Ver. 1.4) software (Applied Biosystems).
Drug combination studies and synergy quantification. The synergy of erlotinib and
MET or erlotinib and AXL inhibitors was evaluated by the Chou-Talalay method [41, http://
www.combosyn.com]. In brief, the cells were treated with 8–12 concentrations of erlotinib
each in combination with 8–12 concentrations of MET or AXL inhibitors. In particular the
ratio of erlotinib with SU11274 was 1:4, while the ratio of erlotinib with PHA-665752 or PF-
04217903 was 1:1. The ratio of erlotinib with the AXL inhibitor was 10:1 as previously reported
[42]. Erlotinib was used at a concentration approximately equal to its IC50 in HCC827 cell line
and at concentrations within 5-fold increments above or below. Each drug was also used alone
at the same concentrations. Cell survival was determined by MTT assays. Each data point was
performed in triplicates. The CompuSyn software (ComboSyn Inc., Paramus, NJ) was used to
determine dose-effect curves for single and combination treatments. Further, combination
index (CI) values were calculated to assess the nature of drug interactions that can be, additive
(CI = 1), antagonistic (CI>1) or synergistic (CI<1). In particular, nonlinear regression tren-
dlines were used to calculate CI. Single and combination dose response curves were entered
into CompuSyn software and the following equation was used: [(D1/Dx1)+(D2/Dx2)], in
which Dx1 is the dose of Drug 1 that inhibits cell survival at x% and Dx2 is the dose of Drug 2
that inhibits cell survival at x% and D1 is the portion of Drug 1 that also inhibits cell survival at
x% in combination with Drug 2 and vice versa. The doses which produced a particular effect
(Dx) can be calculated from the Median effect equation: Dx = Dm [fa/1-fa)]1/m, where, Dm, fa
and fu (1-fa) represent: the median dose, fraction affected and fraction unaffected, respectively.
Dm was estimated from the antilog of the X-intercept of the median effect plot, where X = log
(D) versus Y = log (fa/fu); which means Dm = 10
−(Y-intercept)/m,m being the slope of the median
effect plot.
Statistical analysis. GraphPad Prism software 6.0c was used for MTT data analysis. The
regression trendline were fitted using a non-linear regression method and IC50 values were
determined using a sigmoidal dose response inhibition variable slope method.
In the drug combination studies, dose–effect curve parameters, CI values, Fa-CI plot (plot
representing CI versus Fa, the fraction affected by a particular dose) were calculated by Com-
puSyn program (Compusyn Inc, Paramus, NJ, USA).
In the xenograft experiments the statistical significance of the results was evaluated by two
way analysis of variance and Bonferroni multiple testing to compare differences in tumor fold
growth between ERL-resistant and HCC827 parental cell line. All statistical tests were per-
formed using GraphPad Prism and the threshold for statistical significance was set at P-values
lower than 0.05.
Results and Discussion
Establishment of erlotinib resistant NSCLC cell lines
In order to investigate mechanisms leading to resistance to EGFR-targeted therapy, two
NSCLC cell lines HCC827 and HCC4006 were used to derive in vitromodels of acquired resis-
tance to the EGFR TKI, erlotinib. Both cell lines harbor EGFR activating mutations in the tyro-
sine kinase domain, the HCC827 cell line a deletion in exon 19 (ΔE746-A750) and HCC4006 a
deletion (ΔL747-E749) and a point mutation (A750P) in exon 19. HCC827 and HCC4006 cell
lines are both highly sensitive to TKIs targeting the EGFR. TKI dose-response curves and IC50
values are shown respectively in Fig 1A, Table 1. Specifically, both cell lines respond to erlotinib
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[43] and gefitinib [44] with an IC50 in line with previous reports [26, 45]. Paclitaxel, a member
of the taxane family and an important agent in cancer chemotherapy that acts by binding to
microtubules and interfering with the mitotic process, was used as positive control [46]. Sensi-
tivity to vandetanib [47–49] and to a lesser extent to lapatinib [50], TKIs targeting respectively
VEGFR (Vascular Endothelial Growth Factor Receptor)/EGFR/RET and EGFR/HER2, was
also observed. Imatinib, targeting mainly ABL, PDGFR (Platelet Derived Growth Factor
Fig 1. Cell inhibition growth analysis of ERL-resistant NSCLC cell lines. A) Representative dose-effect curve plots of HCC827 and HCC4006 parental
cell lines to the indicated TKIs. Cell viability was determined by MTT assays. The results are expressed as the percentage of cell viability in drug-treated
cultures relative to DMSO-treated control samples; B) Dose effect curve plots of derived ERL-resistant HCC827 and HCC4006 cell lines. The results are
expressed as described above. Data (mean ± s.e.m) in A and B are representative of more than three independent experiments.
doi:10.1371/journal.pone.0143333.g001
Table 1. IC50 values of TKIs against parental and ERL-resistant NSCLC cell lines.
HCC827 RA1 RA2 RB1 RB1.1 RB2 HCC4006 RC2.2
Erlotinib 4–17 nM >10 μM >10 μM >10 μM >10 μM >10 μM 80–200 nM >10 μM
Gefitinib 4–20 nM >10 μM >10 μM >10 μM >10 μM >10 μM 25–107 nM >10 μM
AZD9291 0.4–10 nM >1 μM >1 μM >1 μM >1 μM >1 μM 1–8 nM >1 μM
Rociletinib 12–32 nM >1 μM >1 μM >1 μM >1 μM >1 μM 100–195 nM >1 μM
Vandetanib 70–180 nM >10 μM >10 μM >10 μM >10 μM >10 μM 310–390 nM >10 μM
Lapatinib 0.5–1.7 μM >10 μM >10 μM >10 μM >10 μM > 10 μM 0.65–1.85 μM > 10 μM
Imatinib >1 μM - - - - - >1 μM -
Paclitaxel 0.1–2 nM 1–4 nM >1 μM 1–4 nM 0.1–2 nM 1–5 nM 0.1–4 nM > 1μM
doi:10.1371/journal.pone.0143333.t001
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Receptor) and c-KIT [51–53] had no effect on both HCC827 and HCC4006 cell lines (Fig 1
and Table 1).
It has been suggested that the features of drug-resistant cells may vary depending on the pro-
tocol used for the selection process [29]. Therefore we derived resistant cell lines by exposing
HCC827 and HCC4006 cell lines (parental) to erlotinib for 5–6 months, following two distinct
protocols essentially as previously described [29]. Briefly, in “protocol 1”, cells were exposed to
increasing concentrations of erlotinib (2x IC50−25/50x IC50), while in “protocol 2” cells were con-
tinuously exposed to a high dose of erlotinib (1 μM). The selection outcomes were monitored
periodically by cell growth inhibition assays by using cells in “drug holiday” for at least 1 week.
Five erlotinib (ERL)-resistant cell lines were isolated from the parental HCC827 cell line, three
with “protocol 1” (RA1, RB1, and RB1.1) and two with “protocol 2” (RA2 and RB2) and one cell
line was obtained from HCC4006 cell line by using “protocol 2” (RC2.2). Several attempts to
derived additional HCC4006 ERL-resistant cell lines with both protocols failed.
All cell lines derived from parental cell lines are resistant to erlotinib and gefitinib (IC50>
10 μM) (Fig 1B, Table 1) as well to the third generation irreversible EGFR inhibitors AZD9291
[54] and Rociletinib (CO-1686, AVL-301) [55] now in advanced stage clinical trials (Table 1) and
highly sensitive to paclitaxel with the exception of RA2 and RC2.2 cell lines that exhibited higher
IC50 values for paclitaxel than those of parental cell lines (Fig 1B, Table 1). Interestingly, the
derived ERL-resistant cell lines are also resistant to inhibitors targeting other RTKs besides EGFR
(Table 1). Importantly the resistant phenotype is stable in the absence of drug selection pressure
thus resembling the phenotype of cancer cells that could survive in patients in drug holiday.
To investigate the tumorigenicity of the ERL-resistant cell lines and verify whether erlotinib
could inhibit their anchorage-independent growth we performed soft agar colony formation
assays. All HCC827 cell lines formed colonies similar in number and size (diameter> 50 μm),
but only the ERL-resistant cell lines formed colonies in presence of erlotinib (Fig 2A). The
HCC4006 and RC2.2 cells formed colonies but smaller in size (diameter< 40–50 μm) and
with lower frequency. Nevertheless, the ERL-resistant RC2.2 cell line was resistant to erlotinib
in soft agar as well (data not shown).
To further investigate the tumorigenicity of the NSCLC cell lines, we performed xenograft
assays in athymic nude mice (Fig 2B). Similar tumor growth curves were recorded for parental
and ERL-resistant HCC827 cell lines with the exception of RA2 xenografts that showed a rele-
vant tumor growth delay (Fig 2B) with statistically different times required to reach a four and
six fold increase from initial tumor volumes (Fig 2C). Since the RC2.2 cell line grows well in
culture but at low cell density (1:5 when compared with the HCC827 parental and derived cell
lines), xenograft assays were performed only with 5x106 cells. In those experimental conditions,
only small nodes and not in all mice were obtained (data not shown). Overall the data demon-
strate that HCC827 ERL-resistant cell lines and, to a lesser extent, RC2.2 cell line are tumori-
genic in anchorage-independent systems. Importantly, even if the selection protocols used
monolayer tissue culture conditions, the derived NSCLC cell lines grow in presence of erlotinib
in 3D model systems, more closely resembling in vivo tissues conditions.
EGFR T790M or KRAS gene mutations are not present in the ERL-
resistant NSCLC cell lines
To verify EGFR and KRAS oncogene mutations, nucleotide sequence analysis of exons 19–20
of the EGFR gene and codons 12/13 and 61 of the KRAS gene was performed with specific
primers listed in S1 Table. We confirmed the presence of mutations in EGFR exon 19 in both
parental and ERL-resistant cell lines and we excluded the presence of an EGFR T790M gene
mutation, the most common cause of acquired resistance to erlotinib in NSCLC patients
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(Table 2). Interestingly, the analysis of pherograms showed in HCC827 only the mutated allele,
likely for its high amplification levels, while in RA2 both allele sequences were detected suggest-
ing a loss of EGFR gene amplification in the mutated allele. Gene copy number analysis by
qPCR confirmed a decrease in EGFR copy number in RA2 cell line (Fig 3). This cell line could
be a useful tool to further investigate the dosage effect of EGFRmutated allele in erlotinib sensi-
tivity. KRAS gene mutations appear to be mainly mutually exclusive with EGFR gene activating
mutations [56–59], however co-occurrence of KRAS and EGFR activating mutations has been
recently reported in Chinese and Indian NSCLC patients [60–61]. KRAS gene codons (12/13,
61) were wild type in all our NSCLC cell lines (Table 2).
Erlotinib binds EGFR and impairs EGFR and ERK1/2 phosporylation
By western blotting analysis we demonstrated that all ERL-resistant cell lines express similar
levels of total and constitutively phosphorylated EGFR and ERK1/2, with the exception of RA2
cell line that showed a strong decrease in EGFR protein levels (Fig 4A). Upon erlotinib
Fig 2. The ERL-resistant HCC827 cells lines are tumorigenic. A) Soft agar colonies were counted by ImageJ software. The percentage of colony forming
efficiency (CFE) of parental (P) and ERL-resistant cell lines, as mean ± s.e.m., is shown. Histograms in gray and white colors indicate respectively vehicle
(DMSO, 0.01%) and ERL (erlotinib 1 μM) cell treatments; B) Tumor volume of xenograft nodes, calculated as described in material and methods, are shown
as mean ± s.e.m; C) Times to four (4x) and six fold (6x) increases from initial tumor volumes (day 3) are shown respectively by white and grey bars. P-
values < 0.0001 are indicated.
doi:10.1371/journal.pone.0143333.g002
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treatment a decrease in EGFR and ERK1/2 phosphorylation signals was observed (Fig 4B) indi-
cating that erlotinib can still bind EGFR and that, unlikely, rare secondary mutations in the
EGFR tyrosine kinase domain are present and/or can impair TKI binding. Furthermore, the
mitogen activated protein kinase (MAPK) downstream targets of the EGFR signaling path-
ways, ERK1/2, are still responsive to erlotinib (Fig 4B). Therefore, while with a partial dephos-
phorylation of EGFR and ERK1/2 proteins we cannot exclude a contribution of EGFR
activation due to intratumoral drug-response heterogeneity, bypass tracks signaling are likely
involved in the ERL-resistant phenotype.
HER2 and HER3 receptors are not overexpressed in ERL-resistant
NSCLC cell lines
Ligand binding to human HERs results in the formation of homo- or heterodimers that acti-
vate RTKs and subsequently downstream signaling pathways including the phosphoinositide
Table 2. Analysis of EGFR and KRAS genemutations.
EGFR Exon 19 EGFR Exon 20 KRAS Exon 2 codons 12/13 KRAS Exon 3 codon 61
HCC827 ΔE746-A750 WT WT WT
RA1 ΔE746-A750 WT WT WT
RA2 WT/ΔE746-A750 WT WT WT
RB1 ΔE746-A750 WT WT WT
RB1.1 ΔE746-A750 WT WT WT
RB2 ΔE746-A750 WT WT WT
HCC4006 ΔE746-A750 WT WT WT
RC2.2 ΔE746-A750 WT WT WT
Cells were analyzed for the mutational status by nucleotides direct sequencing. Δ: E746-A750 deletion of exon 19, WT: wild-type.
doi:10.1371/journal.pone.0143333.t002
Fig 3. Analysis of the EGFR gene in the RA2 ERL-resistant cell line. A) Analysis of EGFR exon 19
nucleotides sequence. The pherogram of the parental cell line with peaks corresponding to the EGFR
mutated sequence (ΔE746-A750) and the pherogram of the RA2 resistant cells with peaks corresponding to
the mutated and wild type (WT) EGFR nucleotides sequence are shown. B) qPCR analysis. Relative EGFR
gene copy number (GCN) in genomic DNA, normalized to the Rnase P gene, is expressed relative to the
levels in parental cell lines (P) set as 1 (mean ± SD of triplicate determinations). Results are representative of
those obtained from 2 independent analysis.
doi:10.1371/journal.pone.0143333.g003
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3-kinase (PI3K)/protein kinase B (AKT) [62]. HER2 amplification and elevated expression of
HER3 are frequently observed in various malignancies including NSCLC [63, 64]. HER3 can
promote tumor progression via interactions with other RTKs due to its lack of or weak intrinsic
kinase activity. To investigate the expression and phosphorylation status of all HER family
members in our model system we performed western blot analysis using parental and ERL-
resistant cell lines. HER2 and HER3 signals were similar in parental and ERL-resistant cell
lines with the exception of RA2 and RC2.2. In particular, RA2 showed very low HER2 expres-
sion and RC2.2 low HER2 and undetectable HER3 signals (Fig 5A). Constitutive phosphoryla-
tion of HER2 (Y1221/1222) and HER3 (Y1289) was detected in all cell lines with the exception
of RA2 and RC2.2 cell lines that showed undetectable or very low signals for pHER2 and
pHER3 (Fig 5A). Notably, the total level of tyrosine phosphorylation was strongly and repro-
ducible reduced in both RA2 and RC2.2 cell lines implying a marked deregulation of kinases
Fig 4. Erlotinib impairs EGFR and ERK1/2 phosphorylation in ERL-resistant cell lines. A) Representative western blots with EGFR and ERK1/2
antibodies and B) pEGFR (Y1068) and pERK1/2 (T202/Y204) antibodies in the indicated parental and ERL-resistant cell lines treated with EGF (100 μg/ml),
ERL (Erlotinib, 100 nM) or vehicle (DMSO) at different time points (8’, 30’, 1hr, 3hrs). Densitometric analyses of band signals were normalized with GAPDH,
the number indicates the signals quantification at 30’ upon ERL-treatment. For RA2 cell line double amount of total cell lysate was loaded to analyze EGFR
expression.
doi:10.1371/journal.pone.0143333.g004
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and/or phosphatases in both cell lines (Fig 5A). HER4 protein was not expressed in parental
and ERL-resistant cell lines (data not shown). Overall, these data suggest that HER2 and HER3
are not overexpressed and therefore unlikely responsible for the ERL-acquired resistance.
Fig 5. HER2/HER3 and AXL expression and phosphorylation analysis. A) Representative western blots of total cell lysates of HCC827 and HCC4006
parental cell lines (P) and their derived ERL-resistant cell lines. Arrows indicate the expected molecular weight size. Total cell lysates loaded were 40 μg for
AXL and pAXL analyses and 25 μg for the others. B) qPCR analysis of AXL mRNA normalized to rp-L31 mRNA and expressed relative to the levels in
parental cell lines set as 1 (mean ± SD of triplicate determinations). Western blots and qPCR data are representative of those obtained respectively from 3
and 2 independent analysis. C) Dose-effect curves were calculated using CompuSyn software and plotting the entered Fa values against the entered dose
values. For combination treatments, the combined drugs dose was entered. Each data point represents the mean of 3 replicates.
doi:10.1371/journal.pone.0143333.g005
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AXL and MET receptor in ERL-resistant NSCLC
Among RTK signaling pathways, previously reported to be involved in mechanisms of ERL-
resistance, we focused our studies on AXL and MET receptors.
AXL is considered a potential relevant target in NSCLC therapy and targeting strategies
with TKIs, aptamers or molecules modulating its turnover are under very active investigation
[65–68]. Moreover, an association of AXL deregulation to ERL-resistance in NSCLC has been
previously reported [24].
AXL expression analysis by western blotting (Fig 5A) and qPCR (Fig 5B), in our model sys-
tem, showed an overexpression of AXL in both HCC827 and HCC4006 ERL-resistant cell lines
independently from the protocol used for selection. However, AXL was constitutively phos-
phorylated (Y779) in both parental and ERL-resistant HCC827 cell lines with the exception of
RA2 (Fig 5A) and not phosphorylated in the RC2.2 cell line. To further investigate the possible
role of AXL on ERL-resistance, cell viability inhibition studies were performed with a selective
AXL inhibitor, R428 [42, 69]. TKI dose-response curves and Dm50 values indicate that AXL
inhibitor alone or in combination with erlotinib did not impair the cell viability of ERL-sensi-
tive and -resistant cell lines (Fig 5C, Table 3). Overall the data suggest that unlikely, in our cell
lines, AXL activation is a key player in the mechanism of ERL-resistance.
We also analyzed the expression levels and constitutive phosphorylation of the serine-threo-
nine kinase AKT. AKT protein was expressed at similar levels in all parental and ERL-resistant
cell lines. Similar constitutive phosphorylation levels of pAKT was observed in all HCC827
ERL-resistant cell lines, a slight and reproducible higher pAKT signal was observed in RC2.2
cell lysates when compared with the HCC4006 cell lysates by western blotting (Fig 5A).
MET has recently emerged as a promising target in NSCLC and targeting strategies are
actively explored in pre-clinical models and in ongoing clinical trials [35–37]. In our cellular
model system we detected an increase inMET gene copy numbers by qPCR in all ERL-resistant
cell lines with the exception of RA2 and RC2.2 cell lines (Fig 6A). MET protein and mRNA
expression, respectively by western blot (Fig 6B) and qPCR (Fig 6C) analysis, confirmed the
higher expression levels of MET in all cell lines harboringMET gene amplification. MET recep-
tor was also constitutively phosphorylated at the Y1234/1235 site in all ERL-resistant cell lines
with the exception of RC2.2 cell line (Fig 6B). Finally, immunohistochemistry studies of xeno-
graft node sections, obtained by mice injected with HCC827 parental and ERL-resistant cell
lines, confirmed the increased expression of MET in the ERL-resistant cell lines harboring
amplifiedMET gene such as RA1 and RB1 when compared with parental and RA2 cell lines
xenograft nodes (Fig 6D). Overall these data confirmed the association of ERL-resistance with
MET gene amplification and overexpression as previously reported [26, 33].
MET overexpression and activation are not sufficient to predict efficacy
of EGFR and MET inhibitors
Several of our HCC827 ERL-resistant cell lines showedMET gene amplification and constitu-
tive MET receptor activation, therefore we decided to investigate the effect on cell growth of
Table 3. Dm50 of single agent and drugs combination for parental and ERL-resistant NSCLC cell lines.
HCC827 RA1 RA2 RB1 RB1.1 RB2 HCC4006 RC2.2
ERL 6–20 nM >10 μM >10 μM >10 μM >10 μM >10 μM 55–61 nM >10 μM
R428 >1 μM >1 μM >1 μM >1 μM >1 μM >1 μM >1 μM >1 μM
ERL+R428 7–11 nM >10 μM >10 μM >10 μM >10 μM >10 μM 47–127 nM >10 μM
Median effect concentrations (Dm50) values are indicated. ERL: Erlotinib
doi:10.1371/journal.pone.0143333.t003
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the following specific MET inhibitors: SU11274 (SU) [70–72], PHA-665752 (PHA) [73–74],
and PF-04217903 (PF) [75–77], and to determine their type of interaction with EGFR inhibi-
tor. Briefly, sensitive and ERL-resistant HCC827 cell lines were treated with SU or erlotinib sin-
gly or in combination using 5-fold dilution series. For combination treatments, a fixed
concentration ratio 1:4 of erlotinib and SU was used. Cell viability data were determined by
MTT and entered as fractional effect (Fa) values into CompuSyn software. Fa values were plot-
ted against the concentration of single drug or drug combinations; representative dose effect
curves are shown in Fig 7. The data indicate that treatment with either MET inhibitor or erloti-
nib did not impair the viability of HCC827 ERL-resistant cell lines while treatments with both
TKIs strongly inhibited the RB1.1 cell line growth. Importantly the RB1.1 showed very low
Dm50 similar to the one recorded in the ERL-sensitive parental cell line (Table 4). Further cal-
culated CI values between 0 and 2 were plotted against Fa values; representative Fa-CI plots are
Fig 6. MET analysis in ERL-resistant cell lines. A) qPCR analysis of gene copy numbers ofMET; B) western blots of total cell lysates with the antibodies
indicated of parental (P) and ERL-resistant cell lines; C) qPCR analysis of MET mRNA expression in parental (P) and ERL-resistant cell lines.MET gene and
mRNA in A) and C) are normalized to RNaseP gene and rp-L31 mRNA respectively and both are expressed relative to the levels in parental cell lines set as 1
(mean ± SD of triplicate determinations). qPCR data are representative of those obtained from 2 independent analysis; D) Confocal microscopy analysis of
MET receptor (green) expression in xenograft nodes of mice subcutaneously injected with the parental HCC827 cells and the ERL-resistant RA1, RB1 and
RA2 cell lines. Images show representative xy-plane maximum projection of the specimens. Scale bars correspond to 15 μm.
doi:10.1371/journal.pone.0143333.g006
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Fig 7. Synergistic effects of Erlotinib and MET inhibitors in ERL-resistant NSCLC cell lines.Dose-effect curves were calculated using CompuSyn
plotting the entered Fa values against the entered dose values. For combination treatments, the combined drugs dose were entered. Each data point
represents the mean of 3 replicates. Combination index (CI) values were generated by non-linear regression method. Trendlines indicate CI values at any
given effect (Fa, fraction affected, %inhibition), actual data points are also shown. CI = 1, additivity; CI >1, antagonism; CI<1, synergy.
doi:10.1371/journal.pone.0143333.g007
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shown in Fig 7. Fa values as well as CI values for the actual experimental data points are shown
along with the drug concentrations used for each point as ratio of the actual dose (Dx) and the
maximal dose (Dmax) used (Fig 7). CI analysis indicated that while the drugs combination was
synergic in all ERL-resistant HCC827 cell lines only in RB1.1 low drug concentrations were
sufficient to impair cell growth by 70–80%. In all other ERL-resistant lines, in particular in
RA2 and RB2, synergy was observed only at high drug concentrations. Remarkably, in RB1.1
cells the majority of experimental points assayed were in the area of the CI plots corresponding
to a % of inhibition 70–80% (Fig 7). To validate these data, two other MET inhibitors, PHA
and PF, were tested in combination with erlotinib in cell viability inhibition assays. The data
essentially similar to the ones obtained with SU and erlotinib confirmed the efficacy of these
combination drugs (Table 4).
Overall the data suggest thatMET gene amplification and receptor activation are not suffi-
cient to predict efficacy of erlotinib plus MET inhibitor treatment in NSCLC with acquired
resistance to erlotinib and that other biomarkers are required for optimal treatment choice.
To further investigate the biochemical mechanisms of the combined treatments, the expres-
sion of MET, EGFR, HER3 and AKT and their phosphorylation status were investigated by
western blotting. In all cell lines, as expected, a strong decrease of MET phosphorylation
(Y1234/1235) was observed upon treatment with SU inhibitor or SU in combination with erlo-
tinib (Fig 8). Furthermore, a decrease of pEGFR (Y1068) levels was observed in parental cell
line treated with erlotinib and in ERL-resistant cell lines treated with the TKIs combination
(Fig 8). These data confirmed the selectivity of SU for MET receptor and indicate that drugs
combination could potentially switch off both receptor-mediated signaling pathways. A com-
plete dephosphorylation of AKT (S473) and HER3 was observed in all ERL-resistant cell lines
only when the cells were treated with both erlotinib and MET inhibitor (Fig 8). However, a par-
tial reduction of pHER3 levels was observed in the ERL-resistant cell lines treated with SU
inhibitor alone indicating likely an effect of SU on HER3-MET heterodimers. In fact MET has
been found to form heterodimers with other RTKs, including EGFR, HER2, HER3 and RET
[78–80, 26, 31].
In summary these data suggest that this TKIs combination treatment can impair both MET
and EGFR signaling pathways but that a strong impact on cell survival can be obtained only in
RB1.1 ERL-resistant NSCLC cell line. Ongoing comparative genome hybridization and RNA
expression array analyses could be instrumental to identify possible mechanisms leading to dif-
ferential response to drug treatment combination and/or biomarkers to predict treatment
efficacy.
Table 4. Dm50 of single agent and drugs combination for parental and ERL-resistant NSCLC cell lines.
HCC827 RA1 RA2 RB1 RB1.1 RB2
ERL 8–30 nM >10 μM >10 μM >10 μM >10 μM >10 μM
SU >20 μM >20 μM >20 μM >20 μM >20 μM >20 μM
ERL+SU 17–150 nM 2.3–4.8 μM >10 μM 3.5–5.8 μM 220–350 nM >10 μM
PHA >10 μM >10 μM >10 μM >10 μM >10 μM >10 μM
ERL+PHA 8–160 nM 2–9 μM >10 μM 2–8.1 μM 70–170 nM >10 μM
PF >10 μM >10 μM >10 μM >10 μM >10 μM >10 μM
ERL+PF 8–45 nM 4.4- >10 μM >10 μM >10 μM 30–50 n M >10 μM
Median effect concentrations (Dm50) values are indicated. ERL, SU, PHA and PF inhibitors: Erlotinib, SU11274, PHA-665752, PF-04217903.
doi:10.1371/journal.pone.0143333.t004
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Conclusion
We have isolated and characterized six ERL-resistant EGFR mutant NSCLC cell lines. We
reported alteration in EGFR amplification in one cell line, AXL overexpression and/or MET
overexpression and activation in ERL-resistant cell lines, consistently with previous studies
indicating that multiple mechanisms may contribute to EGFR TKI treatment resistance. More-
over, our pilot study with EGFR and MET inhibitors demonstrate thatMET gene amplification
and receptor activation are not sufficient to predict a positive effect of drug TKI cocktails on
ERL-resistant NSCLCs highlighting the necessity to search for novel biochemical and molecu-
lar markers guiding treatment choice in ERL-resistant patients and in ongoing clinical trials.
Fig 8. Biochemical analysis of the effects of Erlotinib and MET inhibitors in ERL-resistant NSCLC cell
lines.Western blotting of 8% SDS-PAGE of parental and ERL-resistant HCC827 cells treated with ERL
(erlotinib, 1 μM), SU (SU11274, 4 μM) for 3 hrs. In (a) are shown representative western blots with antibodies
specific for phospho-MET (Y1234/1235), phospho-EGFR (Y1068), phosho-HER3 (Y1289) and phospho-AKT
(S473); in (b) western blots for MET, EGFR, HER3 and AKT proteins.
doi:10.1371/journal.pone.0143333.g008
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